https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf<\/a><\/p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:38:57.347Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "MMR Vaccine"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1522", "label" : {"_value" : "Biography information for Adam Holloway"}
}
, "tablingMemberConstituency" : {"_value" : "Gravesham"}
, "tablingMemberPrinted" : [{"_value" : "Adam Holloway"}
], "uin" : "280999"}
, {"_about" : "http://data.parliament.uk/resources/1140806", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140806/answer", "answerText" : {"_value" : "
Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.<\/p>
The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "280247"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:09:54.417Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Public Health: Disadvantaged"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on health inequalities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "280246"}
, {"_about" : "http://data.parliament.uk/resources/1140807", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140807/answer", "answerText" : {"_value" : "
Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.<\/p>
The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "280246"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:09:54.467Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Public Health: Disadvantaged"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on the health and wellbeing of the most marginalised people in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "280247"}
, {"_about" : "http://data.parliament.uk/resources/1140868", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140868/answer", "answerText" : {"_value" : "
In prison, patients presenting with problematic psychoactive substance use are assessed in the same way as other drug users and offered an appropriate range of psychosocial interventions.<\/p>
In April 2018, NHS England and NHS Improvement published its updated service specification on \u2018Integrated Substance Misuse Treatment Service in Prisons in England\u2019. This is fully aligned to \u2018Drug Misuse and Dependence: UK Guidelines on Clinical Management\u2019, which sets out how clinicians should treat people with drug misuse and drug dependence problems.<\/p>
The service specification describes a fully recovery orientated, integrated prison substance misuse treatment service, which covers traditional drugs of abuse, psychoactive substances (including synthetic cannabis), illicit abuse of prescribed and over the counter drugs and alcohol.<\/p>
This improved substance misuse service offer is now being commissioned across all prisons and secures integration with mental health services so that growing numbers of people in prisons can access services to support their recovery and wellbeing.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:15:47.693Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prisoners: Synthetic Cannabinoids"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what programmes there are in prisons to provide support for prisoners with synthetic cannabis drug dependency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4663", "label" : {"_value" : "Biography information for Ben Bradley"}
}
, "tablingMemberConstituency" : {"_value" : "Mansfield"}
, "tablingMemberPrinted" : [{"_value" : "Ben Bradley"}
], "uin" : "280382"}
, {"_about" : "http://data.parliament.uk/resources/1140869", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140869/answer", "answerText" : {"_value" : "
Information on the availability of therapeutic services for mental health conditions delivered through the Improving Access to Psychological Therapies (IAPT) programme in Nottinghamshire clinical commissioning groups (CCGs)1<\/sup> is not collected.<\/p>Information on waiting times for such services in the Nottinghamshire CCGs in 2019 is in the following table.<\/p>
Month<\/p><\/td> | Number of referrals finishing a course of treatment<\/p><\/td> | Mean wait to enter treatment2<\/sup> (days)<\/p><\/td>Percentage of finishing referrals3<\/sup> seen within 6 weeks<\/p><\/td><\/tr>January 2019<\/p><\/td> | 1,345<\/p><\/td> | 24.3<\/p><\/td> | 83<\/p><\/td><\/tr> | February 2019<\/p><\/td> | 1,290<\/p><\/td> | 24.8<\/p><\/td> | 81<\/p><\/td><\/tr> | March 2019<\/p><\/td> | 1,510<\/p><\/td> | 25.3<\/p><\/td> | 79<\/p><\/td><\/tr> | April 2019<\/p><\/td> | 1,280<\/p><\/td> | 27.4<\/p><\/td> | 76<\/p><\/td><\/tr><\/tbody><\/table> Source: NHS Digital, IAPT dataset<\/p> Notes:<\/p> 1<\/sup> NHS Bassetlaw CCG, NHS Mansfield and Ashfield CCG, NHS Newark and Sherwood CCG, NHS Nottingham City CCG, NHS Nottingham North and East CCG, NHS Nottingham West CCG and NHS Rushcliffe CCG.<\/p>2<\/sup> Waiting time to enter treatment is calculated as the number of days between the referral received date and the first attended treatment appointment. Referral received date and the first treatment appointment dates do not necessarily occur in the same month.<\/p>3<\/sup> In order to finish a course of treatment, a referral must have ended in the month with at least two treatment appointments having been attended in the course of the referral.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:13:47.043Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Health Services: Nottinghamshire"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the (a) availability and (b) waiting times for therapeutic services for mental health conditions in Nottinghamshire.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4663", "label" : {"_value" : "Biography information for Ben Bradley"}
}
, "tablingMemberConstituency" : {"_value" : "Mansfield"}
, "tablingMemberPrinted" : [{"_value" : "Ben Bradley"}
], "uin" : "280383"}
, {"_about" : "http://data.parliament.uk/resources/1140903", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140903/answer", "answerText" : {"_value" : "The NHS Mental Health Implementation Plan 2019/20 \u2013 2023/24 published on 23 July 2019, states that publication of guidance on developing community-based services for adults with eating disorders is imminent.<\/p> <\/p> The guidance for commissioners and providers will aid the development of eating disorder services for adults and to inform sustainability and transformation plans for transforming community services for adults with eating disorders.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:08:19.26Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Eating Disorders: Mental Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when he will publish the adult commissioning guidance on adult eating disorder services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1591", "label" : {"_value" : "Biography information for Tim Farron"}
}
, "tablingMemberConstituency" : {"_value" : "Westmorland and Lonsdale"}
, "tablingMemberPrinted" : [{"_value" : "Tim Farron"}
], "uin" : "280277"}
, {"_about" : "http://data.parliament.uk/resources/1140913", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140913/answer", "answerText" : {"_value" : " The NHS Long Term Plan takes a concerted and systematic approach to reducing health inequalities and addressing unwarranted variation in care. NHS England and NHS Improvement are leading the work through the Maternity Transformation Programme to support maternity services to provide high-quality maternity care for all women.<\/p> Targeted and enhanced continuity of carer can significantly improve outcomes for women from ethnic minorities. The NHS Long Term plan sets out that 75% of black women will receive continuity of carer from midwives by 2024.<\/p> The Department is also funding research to investigate the factors associated with the excess perinatal mortality experienced by black/black British and Asian/Asian British ethnic groups and identify the factors associated with the excess risk of maternal death for black and South Asian women.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:19:04.357Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Maternal Mortality"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the MBRRACE-UK maternal deaths and morbidity statistics 2014-16 showing that (a) Asian women are nearly twice as likely, (b) mixed race women are twice as likely and (c) black women are five times as likely to die during or up to six weeks after pregnancy than white women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4716", "label" : {"_value" : "Biography information for Ruth Jones"}
}
, "tablingMemberConstituency" : {"_value" : "Newport West"}
, "tablingMemberPrinted" : [{"_value" : "Ruth Jones"}
], "uin" : "280405"}
, {"_about" : "http://data.parliament.uk/resources/1140957", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1140957/answer", "answerText" : {"_value" : " Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.<\/p> As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.<\/p> A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.<\/p> All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.<\/p> <\/p> <\/p> <\/strong><\/p> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-07-25", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "280289"}
, {"_value" : "280290"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-25T16:07:40.7Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Metamizole: Side Effects"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
, "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
], "uin" : "280288"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answeringDeptSortName=Health+and+Social+Care&answer.answeringMember.label=Biography+information+for+Dame+Jackie+Doyle-Price", "page" : 0, "startIndex" : 1, "totalResults" : 2180, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
| | |